BML Capital Management’s Satsuma Pharmaceuticals STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-6,440,000
Closed -$4.5M – 35
2023
Q1
$4.5M Hold
6,440,000
– – 3.89% 11
2022
Q4
$5.8M Buy
+6,440,000
New +$18.7M 5.54% 8

BML Capital Management's STSA Position: Q2 2023 in Review

BML Capital Management sold out of Satsuma Pharmaceuticals (STSA) in Q2 2023, closing a stake of 6,440,000 shares — an estimated $4.5M sold.

BML Capital Management first reported a position in STSA in Q4 2022 and held it in 2 quarters. The position peaked at $5.8M in Q4 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

  • BML Capital Management reported no remaining Satsuma Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • BML Capital Management sold 6,440,000 Satsuma Pharmaceuticals shares in Q2 2023, an estimated $4.5M.
  • BML Capital Management first reported a position in Satsuma Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • BML Capital Management's Satsuma Pharmaceuticals position peaked at $5.8M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals as of Q2 2023.

Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.